Acclivity Ventures’ Post

🌟 Exciting Funding Opportunity for Biotech Innovators! 🌟 Are you a part of a UK-based organisation driving groundbreaking research and development in the biomedical sector? If so, you can't afford to miss the "Biomedical Catalyst 2024 Round One: Industry-led R&D"! 🔬 What's on Offer? A chance to secure a minimum of £15 million in grants to propel your innovative projects forward. This is an incredible opportunity to accelerate your R&D efforts and significantly impact the biomedical field. 📅 Key Dates: Opening Date: 2 September 2024, 9:30 AM UK time Closing Date: 16 October 2024, 11:00 AM UK time 🎯 Eligibility: Open to industry-led consortia or companies operating within the UK and focusing on biomedical research. 💡 This grant is designed to support projects that are ready to scale up and achieve commercial success while advancing health outcomes. Whether you're developing new medical technologies, treatments, or diagnostics, this funding could be the catalyst you need. 🔗 https://zurl.co/lnKR 👉 Don't miss this chance to turn your innovative ideas into reality with substantial funding support. Let's drive innovation and create a healthier future together! #BiomedicalResearch #InnovationFunding #UKBiotech #RnD #HealthcareInnovation Connect with us: https://zurl.co/HMll

🌍 Life Science Industry in the UK and EU: A Market on the Rise 🚀 The life science sector in the UK and Europe is experiencing unprecedented growth, cementing its role as a global leader in innovation and healthcare advancements. With a market valued at hundreds of billions of euros, the region is at the forefront of driving breakthroughs in biotechnology, pharmaceuticals, and medical technology. 🔬 The UK has emerged as a top destination for biotech investment, with London and Cambridge leading the way in cutting-edge research and clinical trials. The government's life sciences strategy, combined with regulatory agility, is creating a favorable environment for companies to scale and bring life-changing therapies to market quickly. 🇪🇺 Across Europe, countries like Germany, France, and Switzerland are strengthening their positions in the industry through substantial R&D funding and government support. The EU's emphasis on collaboration and cross-border partnerships accelerates the development of innovations in personalized medicine, AI, and digital health. 💡 The market is also seeing a shift towards sustainability and green practices, with initiatives like the European Green Deal driving companies to align with environmental goals. 🌱 Despite economic challenges, the life sciences sector in the UK and Europe continues to attract talent and investment, shaping the future of healthcare and driving better patient outcomes globally. 🚀🔬🌍 To find out more about the current opportunities we are recruiting in the Life Science industry, head to our website 💻 https://lnkd.in/enuuCf5C #LifeScience #LifeScienceNews #LifeScienceJobs

Here’s how we excel in crafting the perfect study design for your MedTech innovations: 🔍 Methods & Data Agnostic We’re not tied to any specific resources, allowing us to recommend the most appropriate methods and data for your study. This flexibility ensures that we design the most effective study tailored specifically for your product, unlike average CROs who might push predefined solutions. Our team has extensive experience in various research methodologies, which enables us to select the best approach for your unique requirements. 📈 Integrated Expertise in Market Access & Clinical Research Our team combines market access and clinical research expertise to accelerate translational speed and impact. We focus on evidence requirements that expedite your product’s journey to patients rather than academic pursuits. With our deep knowledge in market access strategies, we ensure that your product meets real-world needs quickly and efficiently. 🔬 Customized Solutions for Translational Research We create study designs that are aligned with your product’s development stage and market entry strategy. Unlike typical CROs, we offer customized solutions that enhance both speed and relevance. Our in-house team includes experts in translational research who ensure that every study design is optimized for real-world application. 🚀 Accelerated Design Process Our efficient study design process helps you get started quickly and avoid delays. We ensure that your study design is completed in a timely manner, setting you up for a successful research phase. With a wealth of experience in expediting study designs, we’re committed to fast-tracking your project without compromising quality. 📆 Schedule a chat: discuss your innovation with our VP of Client Relations, Fernanda Nusbaum https://zurl.co/U0kE 📰 TTi's newsletter: Sign up and share! https://lnkd.in/ezh2PSX2 April Zambelli-Weiner, Ph.D. and Fernanda are attending the AdvaMed MedTech conference in Toronto (10/15 – 10/17). https://zurl.co/0Ooq #MedTech #CRO #LitReview #ClinicalResearch #Research #Clinical #StudyManagement #Study #RiskManagement #ValidationStudies #Data #Innovation #MedDevice #EvGen #Evidence #Reimbursement #HECON #HealthEconomics #LitReview #Presentation #Value

Exciting Prospects for Biotech in Boston in 2025! With a tough 2024 nearly finished, Massachusetts is leading the Biotech resurgence, with Boston at the heart of this innovation surge. Looking ahead to 2025, the Greater Boston area is set to further solidify its position as the Biotech capital of the world. Key Highlights: 1. Innovative Ecosystem: Boston’s concentration of intellectual capital and cutting-edge infrastructure makes it an ideal location for groundbreaking research and development. 2. Collaborative Environment: The region’s commitment to interdisciplinary collaboration and access to diverse talent pools is driving forward-thinking solutions in healthcare. 3. State Support: Initiatives like Massachusetts’ Life Sciences 3.0 are paving the way for sustained investment and innovation in the life sciences sector. With companies like Novo Nordisk expanding their research footprint in Boston, the future looks incredibly promising for biotech advancements that will improve patient outcomes worldwide. Very excited to be part of this community and looking forward to a year of transformative growth and discovery in 2025! 🚀🔬 #Biotech #Innovation #Boston #LifeSciences #Healthcare #Massachusetts

📢 Today’s National Biotech and Medtech Development and Commercialisation Summit 2024 in Canberra brings together more than 100 of Australia’s leading industry figures, policy experts, and innovators to shape the future of the nation’s biotech and medtech sectors with a unified voice. #AusBiotech CEO, Rebekah Cassidy, said the Summit comes at pivotal time for Australian life sciences companies including innovators, manufacturers and service providers. “The factors influencing life sciences investment and growth are changing rapidly, which is why it’s crucial that AusBiotech leverage its national convening power to elevate the sector’s voice and lead evidenced-based policy discussions. Now is the time for a unified strategy and roadmap focused on enhancing industry’s development and commercialisation capabilities to bring more life changing medical innovations to market.” MTPConnect CEO Stuart Dignam says nurturing a culture of innovation and focus on commercialisation can make all the difference. “We need a coordinated strategy for backing life sciences innovation and supporting startups and SMEs through the difficult early years of innovation so we capture more opportunities to develop and commercialise sovereign medical products that create jobs, exports and health improvements.” Through this Summit, both organisations hope to provide a clear roadmap to government and industry stakeholders that aligns our policies, funding, and capabilities to accelerate the commercialisation of Australian innovations and position Australia as a global leader. Read today's media release https://lnkd.in/e273weG4 Hon. Jaala Pulford, James Campbell, Karyn McIntosh, Rosanne Hyland, Emma Boscheinen, Robyn Lindner, Dr Marguerite Evans-Galea AM, Britney Toogood, Lisa Dubé, Amelia Vom, Duncan Macinnis, Erin McAllum, Caroline Duell

The Pace of Progress: Addressing the Slowness to Change in Clinical Research 🕰️ In an era defined by rapid technological advancement and shifting global health landscapes, the clinical research industry stands at a critical juncture. While some sectors sprint towards the future, embracing innovation at breakneck speeds, clinical research often seems to navigate change with caution, adhering to a pace that many argue is too slow. But what are the costs of this cautious approach, and more importantly, what can be done to accelerate the pace of progress? The stakes are high; the slower evolution of clinical trials directly impacts drug development timelines, patient access to potentially life-saving treatments, and the overall competitiveness of research institutions and pharmaceutical companies. The roots of this resistance are complex, intertwined with regulatory rigor, the need for absolute data integrity, and an inherent risk aversion that prioritizes patient safety above all. Yet, as we stand on the brink of potential revolutions in personalized medicine, digital health, and artificial intelligence, the question becomes: How can the clinical research industry embrace change without compromising on the core values of safety and efficacy? 🔍 Key Points for Consideration: - Regulatory Evolution: Regulatory bodies are pivotal in shaping the pace of change. How can they become catalysts for innovation, ensuring regulations evolve in tandem with technological advancements? - Cultural Shift: Change is not just about new tools and protocols but also about shifting mindsets within organizations. How can we foster a culture that values agility and innovation, alongside safety and precision? - Collaboration Across Borders: The challenges faced by the clinical research industry are global in nature. How can international collaboration facilitate a more unified approach to adopting new methodologies and technologies? The path forward is not simple, but it is necessary. As we debate the best ways to accelerate progress in clinical research, let us not lose sight of the ultimate goal: to improve patient outcomes and advance human health. 🗣️ I invite you to share your thoughts: - What do you see as the biggest barriers to change within the clinical research industry? - Have you witnessed successful transformations or innovations within your work or organization? What made them possible? Let’s engage in a meaningful discussion on how we can collectively work towards a more dynamic, responsive, and innovative future in clinical research. #ClinicalResearch #Innovation #RegulatoryAffairs #PatientSafety #DigitalHealth #FutureOfMedicine #HealthcareInnovation

🚨 NEW GRANT ALERT: Biomedical catalyst 2024 round one: industry-led R&D 🎯This industry-led R&D competition aims to support SMEs in developing innovative solutions to address health, and healthcare, challenges. 🔑To be in the scope your client's project must: 🔹 Have total project costs between £150,000 and £4 million 🔹Not exceed a grant request of £2 million 🔹Have at least 50% of the total project costs shared by the SMEs, if collaborative 🔹Last between 6 months and 36 months 🔹Carry out all of its project work in the UK 🔹Intend to exploit the results from or in the UK 🔹Start by 1 May 2025 🔹End by 30 September 2028 💰 Funding available: Your project’s total costs must be between £150,000 and £4 million. The total grant cannot exceed £2 million.. 🗓️ Deadline: Wednesday 16 October 2024 11:00 pm. (UK time) Need more information or want to discuss this opportunity further? Let us know, and we'll be happy to assist you and your clients.

Learn about clinical trial global diversification trends in this new report from the IQVIA Institute.

Don't miss this new #IQVIAInstitute report - here are the key findings at a glance: - #ClinicalTrial enrollment duration has risen by 26 % over five years, while country utilization for these trials has declined. - This, coupled with increasing trial complexity and global disruptions, suggests a need to diversify country utilization to mitigate risks. - Significant shifts in country utilization have occurred, with Western Europe and Eastern Europe seeing declines, while North America and China have increased their shares. - A new Clinical Trial Readiness Score allows for country ranking and identification of investment opportunities to optimize underutilized countries. #GlobalHealth

ZiP Diagnostics welcomes the launch of the Medical Science Co-Investment Plan, identifying key investment opportunities in medical devices, complex therapeutics, digital health, and sustainability. Industry and Science Minister Ed Husic MP and Health and Aged Care Minister Mark Butler MP have unveiled the first of seven plans, showcasing a deep understanding of sector drivers and market needs. We support the plan which aims to drive the development of manufacturing in Australia in the medical science sector by increasing industrial capabilities and capacity, supporting the commercialisation of high-value products, and improving the international competitiveness of the medical science and technology sector. We’re also behind the move to improve supply chain diversification to ensure resilience to disruption. ZiP is proudly local in every way. Based in Melbourne, we operate state-of-the-art laboratory and production facilities and all manufacturing is conducted in-house. We're committed to driving innovation and making a meaningful impact in these critical areas. #MedicalScience #InvestmentOpportunities #HealthcareInnovation #GovernmentInitiative #StrategicInvestments #HealthcareTransformation #Innovation #HealthSecurity #AgTech #AdvancedManufacturing #AI #Biotechnology